| scholarly article | Q13442814 |
| retracted paper | Q45182324 |
| P356 | DOI | 10.1158/0008-5472.CAN-04-1145 |
| P698 | PubMed publication ID | 15548700 |
| P50 | author | Varda Rotter | Q16131089 |
| P2093 | author name string | Moshe Oren | |
| Naomi Goldfinger | |||
| Perry Stambolsky | |||
| Lilach Weisz | |||
| Yehudit Cohen | |||
| Amir Zalcenstein | |||
| P2860 | cites work | Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein | Q28238628 |
| Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis | Q28345092 | ||
| Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress | Q28512203 | ||
| The dual role model for p53 in maintaining genomic integrity | Q33538147 | ||
| Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators | Q33737277 | ||
| Impaired prostate tumorigenesis in Egr1-deficient mice | Q33929706 | ||
| Egr-1: is it always immediate and early? | Q34076135 | ||
| Egr1 transcription factor: multiple roles in prostate tumor cell growth and survival | Q34133497 | ||
| The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth | Q34402080 | ||
| Early growth response 1 protein, an upstream gatekeeper of the p53 tumor suppressor, controls replicative senescence | Q34867938 | ||
| Regulation of life and death by the zinc finger transcription factor Egr-1. | Q34972803 | ||
| Involvement of Egr-1/RelA synergy in distinguishing T cell activation from tumor necrosis factor-alpha-induced NF-kappa B1 transcription | Q36376552 | ||
| Transcription factor EGR-1 suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor beta 1. | Q37271247 | ||
| Induction of Egr-1 expression by the retinoid AHPN in human lung carcinoma cells is dependent on activated ERK1/2. | Q38297130 | ||
| EGR1 target genes in prostate carcinoma cells identified by microarray analysis. | Q38308423 | ||
| Inhibition of Egr-1 expression reverses transformation of prostate cancer cells in vitro and in vivo | Q38353133 | ||
| The transcription factor early growth response factor-1 (EGR-1) promotes apoptosis of neuroblastoma cells | Q38354496 | ||
| Egr1 promotes growth and survival of prostate cancer cells. Identification of novel Egr1 target genes | Q38358220 | ||
| Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain | Q39575066 | ||
| p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. | Q39610993 | ||
| Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. | Q40020159 | ||
| The egr-1 gene is induced by DNA-damaging agents and non-genotoxic drugs in both normal and neoplastic human cells. | Q40653480 | ||
| Epidermal growth factor and platelet-derived growth factor induce expression of Egr-1, a zinc finger transcription factor, in human malignant glioma cells | Q40782418 | ||
| The transcription factor EGR-1 directly transactivates the fibronectin gene and enhances attachment of human glioblastoma cell line U251. | Q40883612 | ||
| EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity | Q40896750 | ||
| Early growth response-1-dependent apoptosis is mediated by p53. | Q41094563 | ||
| Lipopolysaccharide induction of the tumor necrosis factor-alpha promoter in human monocytic cells. Regulation by Egr-1, c-Jun, and NF-kappaB transcription factors | Q41099730 | ||
| Binding of MAR-DNA elements by mutant p53: possible implications for its oncogenic functions | Q41141483 | ||
| Gain of function mutations in p53. | Q41557652 | ||
| Inducible expression of Egr-1-dependent genes. A paradigm of transcriptional activation in vascular endothelium | Q41604083 | ||
| Transforming growth factor-alpha-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. | Q41916797 | ||
| The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling | Q43848062 | ||
| Epidermal growth factor and thrombin induced proliferation of immortalized human keratinocytes is coupled to the synthesis of Egr-1, a zinc finger transcriptional regulator | Q43956300 | ||
| p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis | Q44426545 | ||
| Mutant p53 protein expression interferes with p53-independent apoptotic pathways | Q47775780 | ||
| p63 and p73 are required for p53-dependent apoptosis in response to DNA damage | Q59065672 | ||
| Different tumor-derived p53 mutants exhibit distinct biological activities | Q68568861 | ||
| Egr-1-induced endothelial gene expression: a common theme in vascular injury | Q70990718 | ||
| Chemosensitivity linked to p73 function | Q73342473 | ||
| Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation | Q73486628 | ||
| Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth | Q73692134 | ||
| Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth | Q73763323 | ||
| Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants | Q73876727 | ||
| Molecular epidemiology of human cancer | Q74458222 | ||
| Suppression of human fibrosarcoma cell growth by transcription factor, Egr-1, involves down-regulation of Bcl-2 | Q77132887 | ||
| Direct involvement of p53 in the base excision repair pathway of the DNA repair machinery | Q77844569 | ||
| Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy | Q77932308 | ||
| P433 | issue | 22 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 8318-8327 | |
| P577 | publication date | 2004-11-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Transactivation of the EGR1 gene contributes to mutant p53 gain of function | |
| P478 | volume | 64 |
| Q24657532 | A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53 |
| Q94550998 | Cancer and Alzheimer's disease inverse relationship: an age-associated diverging derailment of shared pathways |
| Q61797904 | Cathepsin L activated by mutant p53 and Egr-1 promotes ionizing radiation-induced EMT in human NSCLC |
| Q35669806 | Cathepsin L suppression increases the radiosensitivity of human glioma U251 cells via G2/M cell cycle arrest and DNA damage |
| Q58703983 | Co-Expression Network Analysis Identifies miRNA⁻mRNA Networks Potentially Regulating Milk Traits and Blood Metabolites |
| Q35103336 | Comparison of effects of p53 null and gain-of-function mutations on salivary tumors in MMTV-Hras transgenic mice. |
| Q34409021 | Complementation of two mutant p53: implications for loss of heterozygosity in cancer |
| Q39966300 | Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. |
| Q33776331 | Contribution of p53 to metastasis |
| Q64107824 | Cytarabine-Resistant -ITD Leukemia Cells are Associated with Mutation and Multiple Pathway Alterations-Possible Therapeutic Efficacy of Cabozantinib |
| Q36640204 | Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells |
| Q37423073 | Differential regulation of the REGγ-proteasome pathway by p53/TGF-β signalling and mutant p53 in cancer cells |
| Q35863768 | EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF. |
| Q40148492 | Enhanced angiotensin II production by renal mesangium is responsible for apoptosis/proliferation of endothelial and epithelial cells in a model of malignant hypertension. |
| Q35312427 | Forced expression of heat shock protein 27 (Hsp27) reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene expression in Adriamycin-resistant human breast cancer cells |
| Q38322099 | Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma |
| Q60949960 | ISG15 Promotes ERK1 ISGylation, CD8+ T Cell Activation and Suppresses Ovarian Cancer Progression |
| Q28262992 | Id family of helix-loop-helix proteins in cancer |
| Q39158077 | Identification of common gene networks responsive to mild hyperthermia in human cancer cells. |
| Q43144593 | Increased CD44 gene expression in lymphocytes derived from Alzheimer disease patients. |
| Q43130505 | Interplay between p53 and VEGF: how to prevent the guardian from becoming a villain. |
| Q33755444 | Investigating dynamic and energetic determinants of protein nucleic acid recognition: analysis of the zinc finger zif268-DNA complexes |
| Q22241780 | Li-fraumeni syndrome |
| Q40360196 | Localization of a mutant p53 response element on the tissue inhibitor of metalloproteinase-3 promoter: mutant p53 activities are distinct from wild-type |
| Q36391961 | MicroRNAs, wild-type and mutant p53: more questions than answers |
| Q24302430 | Modulation of the vitamin D3 response by cancer-associated mutant p53 |
| Q92009380 | Molecular changes in solitary fibrous tumor progression |
| Q38403885 | Molecular markers associated with nonepithelial ovarian cancer in formalin-fixed, paraffin-embedded specimens by genome wide expression profiling |
| Q34516626 | Molecular mechanism of mutant p53 stabilization: the role of HSP70 and MDM2. |
| Q30542607 | More targets, more pathways and more clues for mutant p53. |
| Q39787848 | Mutant p53 (G199V) gains antiapoptotic function through signal transducer and activator of transcription 3 in anaplastic thyroid cancer cells |
| Q38870599 | Mutant p53 Gain of Function and Chemoresistance: The Role of Mutant p53 in Response to Clinical Chemotherapy |
| Q30354662 | Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers. |
| Q39615120 | Mutant p53 R248Q but not R248W enhances in vitro invasiveness of human lung cancer NCI-H1299 cells |
| Q24681272 | Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II |
| Q35914917 | Mutant p53 cooperates with ETS2 to promote etoposide resistance |
| Q30537354 | Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion |
| Q79961179 | Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells |
| Q55455939 | Mutant p53 gain of function induces HER2 over-expression in cancer cells. |
| Q46709821 | Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression |
| Q33687048 | Mutant p53 gain-of-function in cancer |
| Q36993572 | Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. |
| Q38977664 | Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist. |
| Q38197826 | Mutant p53 in cancer: new functions and therapeutic opportunities |
| Q39245171 | Mutant p53 in cell adhesion and motility |
| Q40266928 | Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells |
| Q39733945 | Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells |
| Q39297236 | Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity |
| Q47107350 | Mutant p53 partners in crime |
| Q40208079 | Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction |
| Q36661775 | Mutant p53 proteins: between loss and gain of function |
| Q41490261 | Mutant p53 stimulates cell invasion through an interaction with Rad21 in human ovarian cancer cells |
| Q39670597 | Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. |
| Q36293880 | Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF). |
| Q33825046 | Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function |
| Q26776020 | Mutant p53: Multiple Mechanisms Define Biologic Activity in Cancer |
| Q36777355 | Mutant p53: an oncogenic transcription factor |
| Q36070574 | Mutant p53: one name, many proteins |
| Q47600619 | Ninjurin 1 has two opposing functions in tumorigenesis in a p53-dependent manner |
| Q44985584 | Normal colon tissue and colon carcinoma show no difference in heparanase promoter methylation. |
| Q41808246 | Oncogenomic Approaches in Exploring Gain of Function of Mutant p53. |
| Q37221250 | P53 transcriptional activities: a general overview and some thoughts |
| Q39987574 | PRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cells. |
| Q24321834 | PTEN regulation by Akt-EGR1-ARF-PTEN axis |
| Q33359967 | Peptide aptamers targeting mutant p53 induce apoptosis in tumor cells |
| Q34651573 | Preferential binding of hot spot mutant p53 proteins to supercoiled DNA in vitro and in cells. |
| Q38457645 | Preferred binding of gain-of-function mutant p53 to bidirectional promoters with coordinated binding of ETS1 and GABPA to multiple binding sites |
| Q53320298 | Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer. |
| Q80998529 | Reexploring the possible roles of some genes associated with nasopharyngeal carcinoma using microarray-based detection |
| Q40184730 | Regulation of mouse Heparanase gene expression in T lymphocytes and tumor cells. |
| Q28273002 | Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53 |
| Q93109258 | Retraction: Transactivation of the EGR1 Gene Contributes to Mutant p53 Gain of Function |
| Q34686990 | Sensitivity to cisplatin in primary cell lines derived from human glioma correlates with levels of EGR-1 expression. |
| Q81328063 | Single chain antibody against the common epitope of mutant p53 restores wild-type activity to mutant p53 protein |
| Q37300876 | Structural and functional basis for therapeutic modulation of p53 signaling. |
| Q39742354 | TAR1, a human anti-p53 single-chain antibody, restores tumor suppressor function to mutant p53 variants. |
| Q38180665 | TP53 mutants in the tower of babel of cancer progression |
| Q37225303 | The consequence of oncomorphic TP53 mutations in ovarian cancer |
| Q89068692 | The endothelial tumor suppressor p53 is essential for venous thrombus formation in aged mice |
| Q39794563 | The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. |
| Q42503224 | The kinetics of p53-binding and histone acetylation at target promoters do not strictly correlate with gene expression after UV damage. |
| Q36701574 | The oncogenic roles of p53 mutants in mouse models |
| Q38198487 | The paradigm of mutant p53-expressing cancer stem cells and drug resistance |
| Q27686765 | The rebel angel: mutant p53 as the driving oncogene in breast cancer |
| Q90940987 | The transcription and expression profile of p53N236S mutant reveals new aspects of gain of function for mutant p53 |
| Q36777349 | Transcription regulation by mutant p53. |
| Q58616504 | Transcriptional Landscape of PARs in Epithelial Malignancies |
| Q39005896 | Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53. |
| Q38247156 | Transcriptional regulation by mutant p53 and oncogenesis |
| Q40317250 | Tumor suppressor p53 regulates heparanase gene expression |
| Q39614332 | Tumor-derived p53 mutants induce NF-kappaB2 gene expression |
| Q28533490 | Unique anti-glioblastoma activities of hypericin are at the crossroad of biochemical and epigenetic events and culminate in tumor cell differentiation |
| Q37582777 | When mutants gain new powers: news from the mutant p53 field. |
| Q53320356 | [Advances on mutant p53 research]. |
| Q35679117 | p53 Contributes to Differentiating Gene Expression Following Exposure to Acetaminophen and Its Less Hepatotoxic Regioisomer Both In Vitro and In Vivo |
| Q37832072 | p53 and its mutants in tumor cell migration and invasion |
| Q37990283 | p53 at the crossroads between cancer and neurodegeneration |
| Q39935200 | p53 controls hPar1 function and expression |
| Q48100871 | p53 gain-of-function mutations increase Cdc7-dependent replication initiation. |
| Q33376888 | p53 induces distinct epigenetic states at its direct target promoters |
| Q37297983 | p53 inhibition of AP1-dependent TFF2 expression induces apoptosis and inhibits cell migration in gastric cancer cells |
| Q36997392 | p53, BRCA1 and breast Cancer chemoresistance. |
| Q79961068 | p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3 |
| Q91672818 | p53: Multiple Facets of a Rubik's Cube |
| Q53556002 | p53: a two-faced cancer gene. |
| Q45888635 | p53: balancing tumour suppression and implications for the clinic |
| Q38247154 | p53: its mutations and their impact on transcription |
Search more.